How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
Reported cases of hepatotoxicity associated with bosentan therapy have prompted changes to the pulmonary arterial hypertension drug's prescribing information.
Actelion Pharmaceuticals US Inc., which manufactures bosentan (Tracleer), made the changes to highlight the importance of monthly liver function monitoring for the duration of bosentan treatments and the need to...
Read the full article for free courtesy of your local library.
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
